Comparative Pharmacology
Head-to-head clinical analysis: MIRCETTE versus NORINYL 1 50 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRCETTE versus NORINYL 1 50 28 DAY.
MIRCETTE vs NORINYL 1+50 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive